Gelonghui, May 15 | Haofan Biotech (301393.SZ) said on the investor interactive platform that in 2023, the company's export revenue was 127 million yuan, accounting for 32.60% of the annual revenue; 2022 export revenue was 122 million yuan, accounting for 27.26% of the annual revenue. Overseas markets are an important source of revenue for the company. The company has always attached importance to the development and maintenance of overseas customers and the satisfaction of customer needs. Currently, it mainly contacts and communicates with customers by participating in overseas exhibitions, etc. The company has a Ministry of Foreign Trade, where sales staff from the Ministry of Foreign Trade are specifically responsible for sales matters with overseas customers. Up to now, the company has not set up branches overseas, nor has it employed or stationed personnel overseas.
昊帆生物(301393.SZ)：2023年公司外销收入1.27亿元，占全年营业收入比例32.60%
Haofan Biotech (301393.SZ): The company's export revenue in 2023 was 127 million yuan, accounting for 32.60% of the annual revenue
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.